This is an old revision of this page, as edited by InternetArchiveBot(talk | contribs) at 04:18, 21 November 2016(Rescuing 1 sources and tagging 0 as dead. #IABot (v1.2.7.1)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 04:18, 21 November 2016 by InternetArchiveBot(talk | contribs)(Rescuing 1 sources and tagging 0 as dead. #IABot (v1.2.7.1))
A fundamental philosophy of medical oncology, including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent. Because they have different dose-limiting adverse effects, they can be given together at full doses in chemotherapy regimens.[1]
The first successful combination chemotherapy was MOPP, introduced in 1963 for lymphomas.
The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A "maintenance regimen" refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow.[2]
Chemotherapy regimens are often identified by acronyms, identifying the agents used in the drug combination. However, the letters used are not consistent across regimens, and in some cases - for example, "BEACOPP" - the same letter combination is used to represent two different treatments.[3]
There is no widely accepted naming convention or standard for the nomenclature of chemotherapy regimens. For example, either generic or brand names may be used for acronyms. This page merely lists commonly used conventions.
^Kiesewetter B, Mayerhoefer ME, Lukas J, Zielinski CC, Müllauer L, Raderer M (2014). "Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)". Ann. Hematol. 93 (2): 249–53. doi:10.1007/s00277-013-1865-3. PMID23925930.
^El Weshi, A; Memon, M; Raja, M; Bazarbashi, S; Rahal, M; El Foudeh, M; Pai, C; Allam, A; El Hassan, I; Ezzat, A (October 2004). "VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors". American journal of clinical oncology. 27 (5): 529–34. doi:10.1097/01.coc.0000135815.94162.83. PMID15596925.
^Kosmidis, P; Mylonakis, N; Fountzilas, G; Pavlidis, N; Samantas, E; Karabelis, A; Kattis, K; Skarlos, D (July 1996). "A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group". Annals of Oncology. 7 (5): 517–20. doi:10.1093/oxfordjournals.annonc.a010642. PMID8839908.